Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

Sep 26, 2011, 04:10 ET from Reportlinker

NEW YORK, Sept. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

http://www.reportlinker.com/p0629402/Coagulation-Disorders-Market-to-2017---Hemophilia-A-the-Largest-Segment-to-Witness-a-Decline-in-Growth-Rate-due-to-Patent-Expiries-and-Weak-Pipeline.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline", provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2016 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market.

Scope

The scope of this report includes -

- Annualized market data for the coagulation disorders market from 2002 to 2010, forecast forward to 2017.

- Analysis of the leading therapeutic segments, including hemophilia A, hemophilia B, and von Willebrand's disease (vWD).

- Analysis of the coagulation disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the coagulation disorders market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Baxter International Inc, Bayer AG, Novo Nordisk A/S, Pfizer Inc and CSL Behring LLC.

- Key M&A activities and licensing agreements that have taken place between 2004 and 2010 in the global coagulation disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with higher efficiency and better safety.

- Develop strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 9

2.1 GBI Research Report Guidance 9

3 Coagulation Disorders Therapeutics Market: Market Overview 10

3.1 Introduction 10

3.2 Revenue Forecasts for the Global Coagulation Disorders Market 11

3.2.1 Revenue 11

3.2.2 Annual Cost of Therapy 12

3.2.3 Treatment Usage Pattern 13

3.3 Coagulation Disorders Market Drivers 19

3.3.1 Steady Increase in the Prevalence Population, Particularly in the Top Five Countries in Europe 19

3.3.2 Rapid Uptake of Recombinant Products due to Better Efficacy, Safety and Convenient Dosing 19

3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable 20

3.4 Coagulation Disorders Market Restraints 21

3.4.1 Low Diagnosed Population as Mild and Moderate Forms of Coagulation Disorders Go Undiagnosed 21

3.4.2 Patent Expiries of Major Blockbusters Including Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market 21

3.4.3 Sluggish Growth in the Annual Cost of Therapy for Coagulation Disorders is Expected to Drive Down the Growth Rate 21

4 Global Coagulation Disorders Market: Geographical Landscape 22

4.1 Geographical Break-up 22

4.2 The US 24

4.2.1 Revenue 24

4.2.2 Annual Cost of Therapy 25

4.2.3 Treatment Usage Patterns 26

4.3 Top Five Countries in Europe 29

4.3.1 Revenue 29

4.3.2 Annual Cost of Therapy 30

4.3.3 Treatment Usage Pattern 31

4.4 Japan 34

4.4.1 Revenue 34

4.4.2 Annual Cost of Therapy 35

4.4.3 Treatment Usage Patterns 36

5 Coagulation Disorders Therapeutics Market: Therapeutic Landscape 38

5.1 Hemophilia A Market 38

5.1.1 Introduction 38

5.1.2 Revenue 41

5.1.3 Annual Cost of Treatment 45

5.1.4 Treatment Flow Algorithm 46

5.1.5 Treatment Usage Pattern 47

5.2 Hemophilia B Market 50

5.2.1 Introduction 50

5.2.2 Revenue 53

5.2.3 Annual Cost of Treatment 56

5.2.4 Treatment Flow Algorithm 57

5.2.5 Treatment Usage Pattern 58

5.3 von Willebrand Disease (vWD) Market 60

5.3.1 Introduction 60

5.3.2 Revenue 65

5.3.3 Annual Cost of Treatment 68

5.3.4 Treatment Flow Algorithm 69

5.3.5 Treatment Usage Pattern 70

6 Coagulation Disorders Therapeutics Market to 2017: Pipeline Analysis 73

6.1 Introduction 73

6.1.1 Research and Development Pipeline – Hemophilia 74

6.1.2 Research and Development Pipeline – von Willebrand Disease (vWD) 77

6.2 Profiles of Key Late-Stage Drugs in the Coagulation Disorders Market 78

6.2.1 NecLip-pdFVIII 78

6.2.2 Long Acting rFactor VIII 78

6.2.3 OBI-1 79

6.2.4 Recombinant Factor IX Fc Fusion Protein (rFIXFc) 80

6.2.5 NN7008 81

6.2.6 Human-cl rhFVIII 81

6.2.7 BAX 326 82

6.2.8 IB1001 83

6.2.9 NNC-0156-0000-0009 84

6.2.10 Biostate 84

6.2.11 Long Acting rFactor IX 85

7 Global Coagulation Disorders Market: Competitive Landscape 87

7.1 Competitive Profiling 87

7.1.1 Baxter International Inc. 87

7.1.2 Novo Nordisk A/S 89

7.1.3 Pfizer Inc. 91

7.1.4 CSL Behring LLC 93

7.1.5 Bayer AG 94

7.1.6 LFB 95

7.1.7 Grifols 96

7.1.8 Biotest 99

7.1.9 Bio Product Laboratory 100

7.1.10 Octapharma 101

8 Global Coagulation Disorders Market: Strategic Consolidations 104

8.1 Overview 104

8.1.2 Deals by Geography 106

8.1.3 Deals by Value ($) 107

9 Global Coagulation Disorders Market: Appendix 108

9.1 Market Definitions 108

9.2 Abbreviations 108

9.3 Research Methodology 109

9.3.1 Coverage 109

9.3.2 Secondary Research 109

9.3.3 Primary Research 110

9.4 Therapeutic Landscape 110

9.4.2 Market Size by Geography 112

9.5 Geographical Landscape 113

9.6 Pipeline Analysis 113

9.7 Competitive Landscape 113

9.7.1 Expert Panel Validation 113

9.8 Contact Us 113

9.9 Disclaimer 113

9.10 Sources 1141.1 List of Tables

Table 1: Coagulation Disorders Market, Global, Revenue ($bn), 2002–2010 11

Table 2: Coagulation Disorders Market, Global, Revenue ($bn), 2010–2017 11

Table 3: Coagulation Disorders Market, Global, Annual Cost of Therapy ($), 2002–2010 12

Table 4: Coagulation Disorders Market, Global, Annual Cost of Therapy ($), 2010–2017 12

Table 5: Coagulation Disorders Market, Global, Treatment Usage Patterns (thousands), 2002–2010 13

Table 6: Coagulation Disorders Market, Global, Treatment Usage Patterns (thousands), 2010–2017 14

Table 7: Coagulation Disorders Market, Global, Sales Value by Geography ($bn), 2002–2010 22

Table 8: Coagulation Disorders Market, Global, Sales Value by Geography ($bn), 2010–2017 23

Table 9: Coagulation Disorders Market, The US, Revenue ($bn), 2002–2010 24

Table 10: Coagulation Disorders Market, The US, Sales Value ($bn), 2010–2017 24

Table 11: Coagulation Disorders Market, The US, Annual Cost of Treatment ($), 2002–2010 25

Table 12: Coagulation Disorders Market, The US, Annual Cost of Treatment ($), 2010–2017 25

Table 13: Coagulation Disorders Market, The US, Treatment Usage Pattern (thousands), 2002–2010 27

Table 14: Coagulation Disorders Market, The US, Treatment Usage Pattern (thousands), 2010–2017 27

Table 15: Coagulation Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002–2010 29

Table 16: Coagulation Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2010–2017 29

Table 17: Coagulation Disorders Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2002–2010 30

Table 18: Coagulation Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010–2017 30

Table 19: Coagulation Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (thousands), 2002–2010 31

Table 20: Coagulation Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (thousands), 2010–2017 32

Table 21: Coagulation Disorders Market, Japan, Revenue ($m), 2002–2010 34

Table 22: Coagulation Disorders Market, Japan, Revenue ($m), 2010–2017 34

Table 23: Coagulation Disorders Market, Japan, Annual Cost of Treatment ($), 2002–2010 35

Table 24: Coagulation Disorders Market, Japan, Annual Cost of Treatment ($), 2010–2017 35

Table 25: Coagulation Disorders Market, Japan, Treatment Usage Pattern (thousands), 2002–2010 36

Table 26: Coagulation Disorders Market, Japan, Treatment Usage Pattern (thousand), 2010–2017 37

Table 27: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2002–2010 42

Table 28: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2010–2017 42

Table 29: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 45

Table 30: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 45

Table 31: Hemophilia A Therapeutics Market, Global Treatment Usage Pattern (thousand), 2002–2010 48

Table 32: Hemophilia A Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2010–2017 48

Table 33: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2002–2010 53

Table 34: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2010–2017 53

Table 35: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 56

Table 36: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 56

Table 37: Hemophilia B Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002–2010 58

Table 38: Hemophilia B Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2010–2017 59

Table 39: vWD Therapeutics Market, Global, Revenue ($m), 2002–2010 65

Table 40: vWD Therapeutics Market, Global, Revenue ($m), 2010–2017 65

Table 41: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 68

Table 42: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 68

Table 43: vWD Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002–2010 70

Table 44: vWD Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2010–2017 71

Table 45: Hemophilia Therapeutics Market, Global, R&D Pipeline by Phase, 2011 75

Table 46: vWD Therapeutics Market, Global, R&D Pipeline by Phase 77

Table 47: Coagulation Disorders Market, Global, Major M&A Deals, 2008-2010 1051.2 List of Figures

Figure 1: Coagulation Disorders Market, Global, Drivers and Restraints, 2010 10

Figure 2: Coagulation Disorders Market, Global, Revenue ($bn), 2002–2017 11

Figure 3: Coagulation Disorders Market, Global, Annual Cost of Therapy ($), 2002–2017 12

Figure 4: Coagulation Disorders Market, Global, Treatment Usage Pattern (thousands), 2002–2017 13

Figure 5: Coagulation Disorders Market, Global, Diseased Population (thousands), 2002–2017 15

Figure 6: Coagulation Disorders Market, Global, Treatment Seeking Population (thousands), 2002–2017 16

Figure 7: Coagulation Disorders Market, Global, Diagnosed Population (thousands), 2002–2017 17

Figure 8: Coagulation Disorders Market, Global, Prescription Population (thousands), 2002–2017 18

Figure 9: Coagulation Disorders Market, Global, Market Indicators, 2010 20

Figure 10: Coagulation Disorders Market, Global, Market Share by Geography ($bn), 2002–2017 22

Figure 11: Coagulation Disorders Market, The US, Sales Value ($bn), 2002–2017 24

Figure 12: Coagulation Disorders Market, The US, Annual Cost of Treatment ($), 2002–2017 25

Figure 13: Coagulation Disorders Market, The US, Treatment Usage Patterns (thousands), 2002–2017 26

Figure 14: Coagulation Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002–2017 29

Figure 15: Coagulation Disorders Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2002–2017 30

Figure 16: Coagulation Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (thousands), 2002–2017 31

Figure 17: Coagulation Disorders Market, Japan, Revenue ($m), 2002–2017 34

Figure 18: Coagulation Disorders Market, Japan, Annual Cost of Treatment ($), 2002–2017 35

Figure 19: Coagulation Disorders Market, Japan, Treatment Usage Pattern (thousand), 2002–2017 36

Figure 20: Hemophilia A Therapeutics Market, Hemophilia – Disease Cause, 2011 38

Figure 21: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2002–2017 41

Figure 22: Hemophilia A Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2017 43

Figure 23: Hemophilia A Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 44

Figure 24: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 45

Figure 25: Hemophilia A Therapeutics Market, Global, Treatment Flow Algorithm 46

Figure 26: Hemophilia A Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002–2017 47

Figure 27: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2002–2017 53

Figure 28: Hemophilia B Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 54

Figure 29: Hemophilia B Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 55

Figure 30: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 56

Figure 31: Hemophilia B Therapeutics Market, Global, Treatment Flow Algorithm 57

Figure 32: Hemophilia B Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002–2017 58

Figure 33: vWD Therapeutics Market, Global, Revenue ($m), 2002–2017 65

Figure 34: vWD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 66

Figure 35: vWD Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 67

Figure 36: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 68

Figure 37: vWD Therapeutics Market, Global, Treatment Flow Algorithm 69

Figure 38: vWD Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002–2017 70

Figure 39: Coagulation Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), Jul 2011 73

Figure 40: Hemophilia Therapeutics Market, Global, R&D Pipeline by Phase (%), Jul 2011 74

Figure 41: vWD Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77

Figure 42: Coagulation Disorders Market, Global, SWOT - Baxter International Inc, 2011 89

Figure 43: Coagulation Disorders Market, Global, SWOT - Novo Nordisk, 2011 91

Figure 44: Coagulation Disorders Market, Global, SWOT - Pfizer, 2011 92

Figure 45: Coagulation Disorders Market, Global, SWOT - CSL Behring, 2011 94

Figure 46: Coagulation Disorders Market, Global, SWOT - Bayer AG, 2011 95

Figure 47: Coagulation Disorders Market, Global, SWOT - Laboratoire français du Fractionnement et des Biotechnologies, 2011 96

Figure 48: Coagulation Disorders Market, Global, SWOT - Grifols, 2011 99

Figure 49: Coagulation Disorders Market, Global, SWOT - Biotest, 2011 100

Figure 50: Coagulation Disorders Market, Global, SWOT – Bio Products Laboratory, 2011 101

Figure 51: Coagulation Disorders Market, Global, SWOT – Octapharma AG, 2011 103

Figure 52: Coagulation Disorders Market, Global, Deals by Indication (%), 2004-2010 104

Figure 53: Coagulation Disorders Market, Global, Major Licensing Agreements by Geography (%), 2004–2010 106

Figure 54: Coagulation Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2004–2010 107

Figure 55: GBI Research Market Forecasting Model 112

Companies mentioned

Baxter International Inc.

Novo Nordisk A/S

Pfizer Inc.

CSL Behring LLC

Bayer AG

LFB

Grifols

Biotest

Bio Product Laboratory

Octapharma

To order this report:

In Vitro Diagnostic Industry: Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com